
April 24-25: AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients | Chicago
AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients Event: AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients Dates: April 24-25 Location: McCorm ...

April 23-24: IPOG 3rd Annual Minimally Invasive Lung Cancer and Pleural Disease Diagnostics and Treatment Conference | Baltimore
3rd Annual Minimally Invasive Lung Cancer and Pleural Disease Diagnostics and Treatment Conference - Interventional Pulmonary Outcomes Group Event: Interventional Pulmonary Outcomes Group 3rd Annual ...

April 2, 2025: Lumanity Cancer Progress 2025 | NYC
Lumanity Cancer Progress 2025 Event: Cancer Progress Dates: April 2, 2025 Location: New York City NanOlogy representatives will be in New York City for Cancer Progress 2025. Email nanology@DFB.c ...

JDDG: Cutaneous metastases: From epidemiology to therapy
Journal for ImmunoTherapy of Cancer: Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease April 1 ...

Journal for ImmunoTherapy of Cancer: Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer: Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease April 1 ...

NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs
NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs FORT WORTH (February 14, 2024) — NanOlogy LLC, a clinical-st ...

NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC Interim response and peripheral immunomodulation data from its Phase 2 clinical trial of IT LSAM-PTX in stage 3/4 lung ca ...

NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer FORT WORTH (November 20, 2023) — NanOlogy LLC, a clinical-stage oncology ...

NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting FORT WORTH (October 23, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced to ...

Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer Research article published in Pancreas ...